In 2020, the DNBSEQ-T7 Gene Sequencer of Wuhan MGI Technology Co., Ltd. (hereinafter referred to as “MGI”) was approved (Registration No.: G.X.Z.Z. 20,203,220,061).

Stay up-to-date with the latest happenings in the rapidly evolving field of In Vitro Diagnostics (IVD) in China.

Abbott recently said that its Diagnostics business revenues grew 47 percent year over year in the second quarter, driven by sales in its rapid diagnostics business, which reflect results for Alere acquired in October 2017. On an organic bas

Thermo Fisher Scientific recentlyreported a 22 percent increase in second-quarter revenues that was partly driven by acquisitions and increased its revenue and earnings guidance for the year for the second time in a row. We achieved excellen

Recently, Agilent Technologies announced that it has completed the acquisition of ULTRA Scientifics business assets, a supplier of chemical standards and certified reference materials. Agilent identifies chemical standards as a key enabling

Xiamen Spacegen, a provider of oncology molecular diagnostics products and services in China, said recentlythat it hadreceived CE marking for six testing kits. These kits include a human thyroid carcinoma RET gene fusions detection kit, whic

Illumina said after the close of the market recently that it intends to offer approximately $650 million of convertible senior notes due 2023. Illumina also intends to grant the initial purchasers a 30-day optionto purchase up to an addition

Finnish consumer genetic testing firm Negen has turned to BC Platforms for analysis of raw genomic data for clinical reporting purposes, the companies announced recently. Under terms of the new partnership, BC Platforms will run data collect

Bio-Rad Laboratories reported after the close of the market recently that its second quarter revenues increased 14 percent year over year, driven by growth in both its Life Science and Clinical Diagnostics businesses. For the three months e

Expedeon reported today a 106 percent jump in its second quarter revenues as the biological products and services company wrapped up the integration of several recent acquisitions. For the three-month period ended June 30, Expedeon which jus

NEW YORK (GenomeWeb) Shanghai, China-based cancer precision medicine company OrigiMed said today it will collaborate with Illumina to develop oncology assays. The firms will develop the new assays on Illuminas next-generation sequencing inst

Illumina reported after the close of the market on Monday that its second quarter 2018 revenues rose by 25 percent year over year. The San Diego-based genomics technology company reported total Q2 revenues of $830 million, compared to $662 m